Literature DB >> 18424789

Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?

B J Knottnerus1, S Nys, G Ter Riet, G Donker, S E Geerlings, E Stobberingh.   

Abstract

BACKGROUND: Uncomplicated urinary tract infections (UTIs) are common among female patients. According to the national guidelines of the Dutch College of General Practitioners (GPs), the drugs of first and second choice as therapy for UTIs are nitrofurantoin and trimethoprim with resistance percentages of 2% and 23%, respectively. The third choice is fosfomycin tromethamine for which no current resistance data from The Netherlands are available. The aim of this study was to determine these resistance percentages.
METHODS: During 2003-04, urine samples were collected from a representative sample of 21 general practices spread over The Netherlands, the Sentinel Stations of The Netherlands Institute for Health Services Research (NIVEL). Escherichia coli isolated from female patients visiting their GP with symptoms of an acute, uncomplicated UTI were used. Fosfomycin tromethamine susceptibility was determined by Etests. An MIC of fosfomycin tromethamine of 64 mg/L or lower was considered to indicate susceptibility, and MIC values of 96 mg/L or higher were considered to indicate resistance. E. coli ATCC 25922 was used as a reference strain.
RESULTS: In total, 1705 E. coli strains were tested, of which 11 (0.65%) were resistant to fosfomycin tromethamine. The MIC(50) and MIC(90) values for this population were 1 and 4 mg/L, respectively. Within the inhibition zone of 162 susceptible E. coli, resistant mutant colonies were observed, of which after repetition of the susceptibility testing 68 were resistant. In total, 79 (5%) strains were resistant to fosfomycin tromethamine. There was no cross-resistance observed between fosfomycin tromethamine and other antimicrobial agents tested previously.
CONCLUSIONS: The high in vitro susceptibility to fosfomycin tromethamine in this population and the lack of cross-resistance between fosfomycin tromethamine and other agents together with the extensive global clinical experience support the choice of the national guidelines of the Dutch College of GPs to include fosfomycin tromethamine as a therapeutic option in general practice for uncomplicated UTIs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424789     DOI: 10.1093/jac/dkn177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.

Authors:  Vidhya Prakash; James S Lewis; Monica L Herrera; Brian L Wickes; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

Review 2.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

4.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

6.  Differences in the antibiotic susceptibility of human Escherichia coli with poultry-associated and non-poultry-associated extended-spectrum beta-lactamases.

Authors:  T N Platteel; M A Leverstein-Van Hall; J W Cohen Stuart; G M Voets; M P van den Munckhof; J Scharringa; N van de Sande; A C Fluit; M J M Bonten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-22       Impact factor: 3.267

7.  Immediate versus conditional treatment of uncomplicated urinary tract infection - a randomized-controlled comparative effectiveness study in general practices.

Authors:  Ildikó Gágyor; Eva Hummers-Pradier; Michael M Kochen; Guido Schmiemann; Karl Wegscheider; Jutta Bleidorn
Journal:  BMC Infect Dis       Date:  2012-06-28       Impact factor: 3.090

Review 8.  Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy.

Authors:  Constance Schultsz; Suzanne Geerlings
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

9.  Gender and age-dependent etiology of community-acquired urinary tract infections.

Authors:  Enrico Magliano; Vittorio Grazioli; Loredana Deflorio; Antonia Isabella Leuci; Roberto Mattina; Paolo Romano; Clementina Elvezia Cocuzza
Journal:  ScientificWorldJournal       Date:  2012-04-26

10.  The preventive role of transurethral antibiotic delivery in a rat model.

Authors:  Hakki U Ozok; Okan Ekim; Hakan Saltas; Ata T Arikok; Orkun Babacan; Levent Sagnak; Hikmet Topaloglu; Hamit Ersoy
Journal:  Drug Des Devel Ther       Date:  2012-07-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.